Organisation paid for research Program year 2021 Source: CMS Open Payments

Fresenius Management Services Inc

Neither a doctor nor a teaching hospital

Research payments

$1,819,510

312 payments

Through program year 2021, Fresenius Management Services Inc is reported as receiving $1,819,510 in research payments, across 312 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$1,563,142	272
2020	Research	$166,838	27
2019	Research	$89,529	13

Breakdown

Who paid Research payments · program years 2019–2021

Bayer HealthCare Pharmaceuticals Inc. $1,819,510 312 payments

Studies the money was for Research payments · program years 2019–2021

Osocimab in ESRD Phase 2b study $1,306,761 224 payments
Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2 Randomized Double-Blind Placebo-Controlled Study of the Safety Pharmacokinetics and Pharmacodynamics of Multiple Doses of BAY 2976217 $235,414 38 payments
An observer-blind multi-center placebo-controlled parallel group study to assess the safety and tolerability and to characterize the pharmacokinetics and the pharmacodynamics of different doses of BAY 1213790 in patients with end-stage renal disease undergoing hemodialysis $187,805 37 payments
BAY1213790 PK/PD in ESRD patients on dialysis $89,529 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.